Key Takeaways:In its third transaction this year, Solabia has acquired Xebios Diagnostics Group.Solabia strengthens its position in the European diagnostics market with the acquisition of Xebios.Xebios brings expertise in ready-to-use culture media, supplements, and detection kits, which align with Solabia’s existing microbiology activities.Backed by private equity firm Astorg, Solabia continues to strengthen its leadership in diagnostics solutions with the acquisition of Xebios.WHO: Xebios Diagnostics Group manufactures high‑quality ready‑to‑use culture media and test reagents for microbiological diagnostics across water, environmental, clinical, food, beverage, pharmaceutical, and cosmetic applications. With three production sites in Germany and the Netherlands and over 25 years of expertise, Xebios delivers reliable, ISO‑certified products and services that support laboratory quality and efficiency.Founded in 1972, Solabia is a vertically integrated manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, biotechnology, and microbiology industries. Solabia is also a producer of culture media, supplements, and detection kits for food testing, pharmaceutical industry, and microbiology laboratories. With eleven production facilities and multiple R&D centers, Solabia is a major player in the global cosmetics, nutraceutical, and pharmaceutical ingredient markets, with presence in North and South America, Europe, Asia, the Middle East, and Africa. WHY: Through this acquisition, Solabia significantly reinforces and expands its European diagnostics footprint and activities.